Invention Grant
- Patent Title: Heterocyclic compound and use thereof
-
Application No.: US16256773Application Date: 2019-01-24
-
Publication No.: US10654874B2Publication Date: 2020-05-19
- Inventor: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@24692ba3
- Main IPC: C07D513/04
- IPC: C07D513/04

Abstract:
Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
Public/Granted literature
- US20190263832A1 HETEROCYCLIC COMPOUND AND USE THEREOF Public/Granted day:2019-08-29
Information query